The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessing the significance of KRAS G12C mutation: Clinicopathologic features, treatments, and survival outcomes in a real-world KRAS mutant non-small cell lung cancer cohort.
 
Wanyuan Cui
No Relationships to Disclose
 
Fanny Franchini
No Relationships to Disclose
 
Marliese Alexander
Travel, Accommodations, Expenses - Dr. Reddy's Laboratories; Roche Molecular Diagnostics
 
Ann Officer
No Relationships to Disclose
 
Hui Li Wong
No Relationships to Disclose
 
Maarten J. IJzerman
Travel, Accommodations, Expenses - Illumina (Inst)
 
Jayesh Desai
Consulting or Advisory Role - Amgen (Inst); BeiGene; Biocon; Eisai; Lilly
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); Roche (Inst)
 
Benjamin J. Solomon
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Loxo; Merck Sharp & Dohme; Pfizer (Inst); Roche/Genentech
Research Funding - Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Veristrat (Biodesix); UpToDate